Cyclic helix B peptide ameliorates acute myocardial infarction in mice by inhibiting apoptosis and inflammatory responses.
Cheng YangChao ZhangJianguo JiaLingyan WangWeitao ZhangJiawei LiMing XuRuiming RongTongyu ZhuPublished in: Cell death discovery (2019)
Cyclic helix B peptide (CHBP) is a peptide derivant of erythropoietin with powerful tissue-protective efficacies in a variety of organ injuries, but without erythropoietic effect. However, the role of CHBP in acute myocardial infarction (AMI) and related mechanisms are not studied yet. In this study, we found in a murine AMI model that the administration of CHBP could ameliorate cardiac injury, increase the survival rate, inhibit cardiomyocyte apoptosis, improve cardiac function and remodeling, and reduce the expression of inflammatory cytokines in the serum and kidney tissue both at 24 h and 8 weeks following AMI. This study suggests that CHBP has the potential to be used as an effective drug in the treatment of AMI.
Keyphrases
- acute myocardial infarction
- percutaneous coronary intervention
- left ventricular
- oxidative stress
- endoplasmic reticulum stress
- cell death
- acute coronary syndrome
- poor prognosis
- cell cycle arrest
- signaling pathway
- coronary artery disease
- transcription factor
- climate change
- long non coding rna
- risk assessment
- binding protein
- recombinant human
- pi k akt
- human health